Ventyx Biosciences 将来の成長

NasdaqGS:VTYX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	18	-183	-202	-168	5
12/31/2025	N/A	-170	-165	-166	7
12/31/2024	N/A	-144	-86	-133	7
9/30/2024	N/A	-153	-160	-159	N/A
6/30/2024	N/A	-171	-159	-158	N/A
3/31/2024	N/A	-193	-184	-183	N/A
12/31/2023	N/A	-193	-167	-167	N/A
9/30/2023	N/A	-181	-163	-162	N/A
6/30/2023	N/A	-158	-152	-151	N/A
3/31/2023	N/A	-125	-117	-117	N/A
12/31/2022	N/A	-108	-99	-99	N/A
9/30/2022	N/A	-91	-66	-66	N/A
6/30/2022	N/A	-73	-54	-53	N/A
3/31/2022	N/A	-69	-49	-48	N/A
12/31/2021	N/A	-85	-39	-39	N/A
9/30/2021	N/A	-84	-26	-26	N/A
6/30/2021	N/A	-79	-17	-17	N/A
3/31/2021	N/A	-65	-8	-8	N/A
12/31/2020	N/A	-28	-6	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VTYX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VTYX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VTYX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VTYX来年は収益がないと予測されています。

高い収益成長: VTYX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VTYXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Ventyx Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 10.0% to US$10.00

Price target increased by 9.8% to US$11.75

Price target increased by 13% to US$10.90

Price target increased by 8.9% to US$9.67

Price target decreased by 26% to US$40.20

Price target increased by 7.8% to US$55.45

Recent updates

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Ventyx Biosciences, Inc. Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. Announces Executive Appointments

Ventyx Biosciences, Inc. Announces CFO Changes

Price target decreased by 10.0% to US$10.00

Price target increased by 9.8% to US$11.75

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of Vtx958 in Participants with Moderately to Severely Active Crohn’S Disease

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Ventyx Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Price target increased by 13% to US$10.90

Ventyx Pivots To Obesity Amid Transformation

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm

Price target increased by 8.9% to US$9.67

New major risk - Revenue and earnings growth

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Founder recently sold US$125k worth of stock

Founder notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Executive Changes

New major risk - Revenue and earnings growth

Price target decreased by 26% to US$40.20

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis

Chief Business Officer notifies of intention to sell stock

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

President & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Ventyx Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New minor risk - Share price stability

President & Chief Medical Officer notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

President & Chief Medical Officer exercised options and sold US$362k worth of stock

President & Chief Medical Officer exercised options and sold US$118k worth of stock

Ventyx Biosciences, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Financial Officer exercised options and sold US$968k worth of stock

Chief Financial Officer exercised options and sold US$207k worth of stock

Executive Chair exercised options and sold US$2.8m worth of stock

Price target increased by 7.8% to US$55.45

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Price target increased by 7.6% to US$55.50

Independent Director exercised options and sold US$969k worth of stock

Ventyx Biosciences, Inc. Announces Board Appointments

Founder recently sold US$1.7m worth of stock

President & Chief Medical Officer exercised options and sold US$1.4m worth of stock

Chief Scientific Officer recently sold US$1.2m worth of stock

Chief Financial Officer exercised options and sold US$1.3m worth of stock

Founder recently sold US$8.7m worth of stock

Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

High number of new directors

Ventyx Biosciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ventyx Biosciences: Not Chasing This Rally

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences, Inc. Announces Positive Data from its Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of VTX958, Novel and Selective Allosteric TYK2 Inhibitor

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Ventyx Biosciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022